Literature DB >> 12639062

How quality of life data contribute to our understanding of cancer patients' experiences? A study of patients with lung cancer.

Ali Montazeri1, Robert Milroy, David Hole, James McEwen, Charles R Gillis.   

Abstract

A prospective study was conducted to measure quality of life in newly diagnosed lung cancer patients attending a chest clinic in a large teaching and district general hospital in a geographically defined area (northern sector of Glasgow, Scotland). Quality of life was assessed at two points in time, pre-diagnosis (baseline) and 3 months after diagnosis (follow-up) using three standard measures; the Nottingham Health Profile (NHP); the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), and its lung cancer supplement (QLQ-LC13). Out of 133 lung cancer patients diagnosed during the study period, 129 patients (97%) were interviewed pre-diagnosis. Of these, only 63% of the patients had an active treatment. Ninety-six patients were alive at follow-up, of whom 82 patients were re-interviewed. Thus, only 82 patients who had complete data were used in the analysis. Comparing patients' pre-diagnosis and follow-up scores on the NHP, only sleep difficulties improved slightly. Patients reported increased perceived health problems of all other characteristics studied (energy, p = 0.0004; physical mobility, p = 0.0008). Similar results were observed on the EORTC questionnaires indicating that patients' functioning and global quality of life had decreased. The only significant improvement after 3 months was seen in patients' cough (p = 0.006). There were marked increases in hair loss (p < 0.0001), constipation (p = 0.007), and sore mouth (p = 0.0004). The findings suggest that patient-centred variables should receive sufficient consideration in the treatment of lung cancer. The study results clearly indicate that information on quality of life contributes to our understanding of patients' experiences of their cancer treatment.

Entities:  

Mesh:

Year:  2003        PMID: 12639062     DOI: 10.1023/a:1022232624891

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  37 in total

1.  Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

Authors:  R L Souhami; S G Spiro; R M Rudd; M C Ruiz de Elvira; L E James; N H Gower; A Lamont; P G Harper
Journal:  J Natl Cancer Inst       Date:  1997-04-16       Impact factor: 13.506

2.  Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?

Authors:  P A Ganz; R A Figlin; C M Haskell; N La Soto; J Siau
Journal:  Cancer       Date:  1989-04-01       Impact factor: 6.860

3.  Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated accelerated [correction of acclerated] radiotherapy (CHART) randomized trial in non-small-cell lung cancer. CHART Steering Committee.

Authors:  A J Bailey; M K Parmar; R J Stephens
Journal:  J Clin Oncol       Date:  1998-09       Impact factor: 44.544

Review 4.  Chemotherapy in the management of patients with inoperable non-small cell lung cancer.

Authors:  D N Carney
Journal:  Semin Oncol       Date:  1996-12       Impact factor: 4.929

5.  Women with lung cancer: impact on quality of life.

Authors:  L Sarna
Journal:  Qual Life Res       Date:  1993-02       Impact factor: 4.147

6.  Assessment of 'quality of life' using a daily diary card in a randomised trial of chemotherapy in small-cell lung cancer.

Authors:  N H Gower; R M Rudd; M C Ruiz de Elvira; S G Spiro; L E James; P G Harper; R L Souhami
Journal:  Ann Oncol       Date:  1995-07       Impact factor: 32.976

7.  Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).

Authors:  R A Joss; P Alberto; C Hürny; M Bacchi; S Leyvraz; B Thürlimann; T Cerny; G Martinelli; R Stahel; C Ludwig
Journal:  Ann Oncol       Date:  1995-01       Impact factor: 32.976

8.  Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).

Authors:  R A Joss; M Bacchi; C Hürny; J Bernhard; T Cerny; G Martinelli; S Leyvraz; H J Senn; R Stahel; P Siegenthaler
Journal:  Ann Oncol       Date:  1995-02       Impact factor: 32.976

9.  A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer research Campaign trial.

Authors:  L E James; N H Gower; R M Rudd; S G Spiro; P G Harper; C W Trask; M Partridge; M C Ruiz de Elvira; R L Souhami
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

10.  Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.

Authors:  H Anderson; P Hopwood; R J Stephens; N Thatcher; B Cottier; M Nicholson; R Milroy; T S Maughan; S J Falk; M G Bond; P A Burt; C K Connolly; M B McIllmurray; J Carmichael
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

View more
  24 in total

1.  Exercise preferences, levels and quality of life in lung cancer survivors.

Authors:  H J Leach; J A Devonish; D G Bebb; K A Krenz; S N Culos-Reed
Journal:  Support Care Cancer       Date:  2015-04-02       Impact factor: 3.603

2.  A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment.

Authors:  Timothy J Williamson; Alyssa K Choi; Julie C Kim; Edward B Garon; Jenessa R Shapiro; Michael R Irwin; Jonathan W Goldman; Krikor Bornyazan; James M Carroll; Annette L Stanton
Journal:  J Thorac Oncol       Date:  2018-07-05       Impact factor: 15.609

3.  Patients and carer experiences of care provision after a diagnosis of lung cancer in Scotland.

Authors:  Meinir Krishnasamy; Mary Wells; Erna Wilkie
Journal:  Support Care Cancer       Date:  2006-09-02       Impact factor: 3.603

4.  Long-term effect of pulsed high-intensity laser therapy in the treatment of post-mastectomy pain syndrome: a double blind, placebo-control, randomized study.

Authors:  Anwar Abdelgayed Ebid; Ahmed Mohamed El-Sodany
Journal:  Lasers Med Sci       Date:  2015-06-27       Impact factor: 3.161

5.  Effect of lung cancer surgery on quality of life.

Authors:  T Win; L Sharples; F C Wells; A J Ritchie; H Munday; C M Laroche
Journal:  Thorax       Date:  2005-03       Impact factor: 9.139

6.  Satisfaction with information and its association with illness perception and quality of life in Indonesian breast cancer patients.

Authors:  Aulia Iskandarsyah; Cora de Klerk; Dradjat R Suardi; Monty P Soemitro; Sawitri S Sadarjoen; Jan Passchier
Journal:  Support Care Cancer       Date:  2013-06-18       Impact factor: 3.603

7.  Quality-of-life measures as predictors of post-esophagectomy survival of patients with esophageal cancer.

Authors:  Yu-Ling Chang; Yun-Fang Tsai; Yin-Kai Chao; Meng-Yu Wu
Journal:  Qual Life Res       Date:  2015-08-04       Impact factor: 4.147

8.  Posttraumatic Symptoms, Quality of Life, and Survival among Lung Cancer Patients.

Authors:  Angela Liegey Dougall; Jeffrey Swanson; Yasushi Kyutoku; Chandra P Belani; Andrew Baum
Journal:  J Appl Biobehav Res       Date:  2017-04-18

Review 9.  Genetic testing for Lynch syndrome in the first year of colorectal cancer: a review of the psychological impact.

Authors:  Karin M Landsbergen; Judith B Prins; Han G Brunner; Floris W Kraaimaat; Nicoline Hoogerbrugge
Journal:  Fam Cancer       Date:  2009-03-28       Impact factor: 2.375

Review 10.  Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008.

Authors:  Ali Montazeri
Journal:  Health Qual Life Outcomes       Date:  2009-12-23       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.